Alan Brochstein
Alan Brochstein
Send Message
Alan Brochstein
Stop FollowingAlan Brochstein
View as an RSS Feed
COMMENTS STATS
1,709 Comments
1,602 Likes

Google Could Break $670.25 By 2014 [View article]
An Exciting New Technology That Could Take Pressure Off St. Jude Medical [View article]
Sliced In Half: 7 Mid-Cap Disasters Worth A Look [View article]
Fast Casual Potential Makes Red Robin Shares An Opportunity [View article]
An Exciting New Technology That Could Take Pressure Off St. Jude Medical [View article]
An Exciting New Technology That Could Take Pressure Off St. Jude Medical [View article]
I wasn't trying to criticize you about not knowing STJ but rather to point out how sad it is that only 354 are signed up for alerts.
An Exciting New Technology That Could Take Pressure Off St. Jude Medical [View article]
Do Buybacks Destroy Shareholder Value? [View article]
http://on.ft.com/L76bqZ
Biglari Holdings Annual Meeting Notes: CEO Inspires Confidence [View article]
Sliced In Half: 7 Mid-Cap Disasters Worth A Look [View article]
Where Do You Value Met Pro? [View article]
Is 9% A Realistic Long-Term Rate Of Return For U.S. Equities? [View article]
Young Robots Lenny And Mona All Grown Up Now, But Intuitive Surgical Is No Cost Cutter [View article]
You should take a look at IRBT. I have been watching it for a year without yet getting involved in my model portfolio, but I sure like it here at 22.50 or so. The reason I mention is that their Ava robot has an initial application for healthcare (not surgery). The company is tough to value - requires optimism! They have the booming Roomba biz, supported by shockingly strong international adoption and fueled by LatAm this year and China next year, and they have the cratered defense and security biz. I think that this beaten-down part of their business will come out of the fiscal challenges well ultimately - it's just not that much of a dollar investment in the scheme of things.
Young Robots Lenny And Mona All Grown Up Now, But Intuitive Surgical Is No Cost Cutter [View article]
Additionally, one of the big drivers is that Japan has only recently approved the Da Vinci, and this could really add to the story over time (I include it in my valuation multiple).
Finally, I am not sure of your title - perhaps the editors changed it, or maybe it was yours. I think that there is a healthy debate there, and you seem to point to it in the body of the article. I wouldn't want to conclude that it's not a cost-cutter, though. Ultimately cost to the healthcare system is dependent on outcomes. There are many studies suggesting fewer hospital days and fewer complications due to the use of Da Vinci. I think that this is especially true with more experienced users - there is a learning curve. Hospitals are financially strapped - why would they be buying these things if they didn't believe that ultimately it lowers their cost? Maybe just to keep revenue???
Sliced In Half: 7 Mid-Cap Disasters Worth A Look [View article]
I am not aware of pressure as being the determining factor for sand vs. ceramic. I have a client who is going to talk to EOG's CEO about this later this week (I think today actually). Is there a source you can cite for this information? If it were entirely true, then their overall sales by pounds would be down, which they are not.